ASCO25 Update: Tres Uramigas Highlighted Data on ADC and PD-1 Combinations in Bladder Cancer

Tres Uramigas shared a post on X:

“ASCO25: ADC/PD-1 combos data in Bladder Cancer.

Nectin4/PD-1 response rates similar to EVP

DV/Toripalimab exceeds QT in 1L. A new therapeutic scenario opens up in which QT could cease to be SoC in 1L.”

ASCO25